AMNEAL PHARMACEUTICALS, INC. Foreign Currency Transaction Gain (Loss), Unrealized
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$10.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$2.28M, a 127.75% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$8.21M, a 328.45% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$1.15M.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was -$3.21M, a 213.16% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for fiscal 2025 was $7.45M.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for fiscal 2024 was -$7.19M, a 1036.33% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for fiscal 2023 was $768.00K.
- AMNEAL PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for fiscal 2022 was -$15.19M.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$10.49M 10-Q · filed 2026-08-06 | -$11.65M derived: sum of 3 quarters · filed 2026-08-06 | -$14.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$8.21M 10-Q · filed 2026-05-07 | -$9.37M derived: sum of 2 quarters · filed 2026-05-07 | -$12.57M derived: sum of 3 quarters · filed 2026-05-07 | -$4.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$4.36M derived: sum of 2 quarters · filed 2026-02-27 | $3.86M derived: sum of 3 quarters · filed 2026-08-06 | $7.45M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.01M derived: sum of 2 quarters · filed 2026-08-06 | $8.61M 10-Q · filed 2025-11-06 | $661.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.81M 10-Q · filed 2026-08-06 | $3.87M derived: sum of 3 quarters · filed 2026-08-06 | $6.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.60M 10-Q · filed 2026-05-07 | -$4.35M derived: sum of 2 quarters · filed 2026-05-07 | -$1.51M derived: sum of 3 quarters · filed 2026-05-07 | -$2.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$5.11M derived: sum of 2 quarters · filed 2026-02-27 | -$5.68M derived: sum of 3 quarters · filed 2026-02-27 | -$7.19M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.27M derived: sum of 2 quarters · filed 2025-11-06 | $754.00K 10-Q · filed 2025-11-06 | $3.08M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$569.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.08M 10-Q · filed 2025-08-07 | $251.00K derived: sum of 3 quarters · filed 2026-02-27 | -$2.87M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$1.51M 10-Q · filed 2025-05-07 | $820.00K derived: sum of 2 quarters · filed 2026-02-27 | -$2.30M derived: sum of 3 quarters · filed 2026-02-27 | -$2.73M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$793.00K derived: sum of 2 quarters · filed 2026-02-27 | -$1.22M derived: sum of 3 quarters · filed 2026-02-27 | $768.00K 10-K · filed 2026-02-27 |
| 2023-09-30 | -$3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.55M derived: sum of 2 quarters · filed 2024-11-12 | -$1.56M 10-Q · filed 2024-11-12 | -$3.86M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$426.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.56M 10-Q · filed 2024-08-09 | -$736.00K derived: sum of 3 quarters · filed 2025-02-28 | -$5.62M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.99M 10-Q · filed 2024-05-08 | -$310.00K derived: sum of 2 quarters · filed 2025-02-28 | -$5.19M derived: sum of 3 quarters · filed 2025-02-28 | -$10.06M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$7.18M derived: sum of 2 quarters · filed 2025-02-28 | -$12.05M derived: sum of 3 quarters · filed 2025-02-28 | -$15.19M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$9.75M derived: sum of 2 quarters · filed 2023-11-09 | -$12.89M 10-Q · filed 2023-11-09 | -$13.16M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$4.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$8.01M 10-Q · filed 2023-08-08 | -$8.28M derived: sum of 3 quarters · filed 2024-03-14 | -$8.06M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$3.14M 10-Q · filed 2023-05-09 | -$3.41M derived: sum of 2 quarters · filed 2024-03-14 | -$3.19M derived: sum of 3 quarters · filed 2024-03-14 | -$5.29M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$51.00K derived: sum of 2 quarters · filed 2024-03-14 | -$2.15M derived: sum of 3 quarters · filed 2024-03-14 | -$175.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $218.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$1.88M derived: sum of 2 quarters · filed 2022-11-07 | $94.00K 10-Q · filed 2022-11-07 | $9.04M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$124.00K 10-Q · filed 2022-08-08 | $8.82M derived: sum of 3 quarters · filed 2023-03-03 | $17.86M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $1.97M 10-Q · filed 2022-05-06 | $10.92M derived: sum of 2 quarters · filed 2023-03-03 | $19.95M derived: sum of 3 quarters · filed 2023-03-03 | $24.21M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $8.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $17.98M derived: sum of 2 quarters · filed 2023-03-03 | $22.24M derived: sum of 3 quarters · filed 2023-03-03 | $16.73M 10-K · filed 2023-03-03 |
| 2020-09-30 | $9.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $13.29M derived: sum of 2 quarters · filed 2021-11-08 | $7.78M 10-Q · filed 2021-11-08 | $10.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $4.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$1.25M 10-Q · filed 2021-08-09 | $1.96M derived: sum of 3 quarters · filed 2022-03-01 | -$12.29M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$5.51M 10-Q · filed 2021-05-07 | -$2.30M derived: sum of 2 quarters · filed 2022-03-01 | -$16.55M derived: sum of 3 quarters · filed 2022-03-01 | -$6.37M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$11.04M derived: sum of 2 quarters · filed 2022-03-01 | -$852.00K derived: sum of 3 quarters · filed 2022-03-01 | -$7.34M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$14.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$4.06M derived: sum of 2 quarters · filed 2020-11-06 | -$10.55M 10-Q · filed 2020-11-06 | -$7.57M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $10.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $3.69M 10-Q · filed 2020-08-06 | $6.67M derived: sum of 3 quarters · filed 2021-03-01 | $2.15M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$6.49M 10-Q · filed 2020-05-11 | -$3.51M derived: sum of 2 quarters · filed 2021-03-01 | -$8.04M derived: sum of 3 quarters · filed 2021-03-01 | -$33.40M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$1.55M derived: sum of 2 quarters · filed 2021-03-01 | -$26.91M derived: sum of 3 quarters · filed 2021-03-01 | -$18.58M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$29.89M derived: sum of 2 quarters · filed 2019-11-07 | -$21.56M 10-Q · filed 2019-11-07 | -$18.43M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$25.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$17.03M 10-Q · filed 2019-08-05 | -$13.90M derived: sum of 3 quarters · filed 2020-03-02 | -$19.30M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $8.33M 10-Q · filed 2019-05-09 | $11.46M derived: sum of 2 quarters · filed 2020-03-02 | $6.06M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$2.27M derived: sum of 2 quarters · filed 2020-03-02 | $30.82M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $27.69M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $33.09M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$12.16M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |